Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
08/22/2011
Trade Name:
Copegus and PEGASYS
Generic or Proper Name (*):
ribavirin and peginterferon alfa-2a
Indications Studied:
Treatment of chronic hepatitis C in patients 5 to 17 years of age
Therapeutic Category:
Antiviral
Ages Studied:
5-17 years
Study #:
2
Study Type:
Safety/Pharmacokinetics
Study Design:
Open Label/Trad PK
No Patients:
14
No Centers:
5
No Countries:
1
BPCA(B), PREA(P):
P
-
-